Medanta eyes 5,000-bed capacity; to add 300 in Noida in FY25

Global Health Ltd. (Medanta) recorded a robust 59% compound annual growth rate earnings over FY20-FY24, led by superior execution. Motilal Oswal has pegged 18% CAGR over FY24-FY26.

Given that Medanta is implementing efforts to further scale up Lucknow/Patna, expand its bed capacity, and add clinical talent, we witness moderate earnings in FY25. However, we expect robust earnings growth from FY26 onwards, said Motilal Oswal.

We value Medanta at 33 times 12 months forward enterprise value/EBITDA to arrive at a target price of Rs 1,380. We reiterate Buy on the stock, added Motilal Oswal.

For full report, click. Motilal Oswal